Pericardial Effusion Secondary to Nilotinib in an Elderly Patient With Chronic Myelogenous Leukemia.
Publication/Presentation Date
4-1-2022
Abstract
Tyrosine kinase inhibitors (TKIs) are the first-line treatment for patients with chronic myelogenous leukemia (CML). Serositis, including pleural and pericardial effusions, is a frequent adverse event with some TKIs while less frequent with others. We present a case of a 76-year-old woman with CML on nilotinib who presented with progressive fatigue and was eventually found to have cardiac tamponade from a large pericardial effusion attributed to nilotinib. The patient required urgent therapeutic pericardiocentesis and switching of TKIs from nilotinib to bosutinib.
Volume
14
Issue
4
First Page
23855
Last Page
23855
ISSN
2168-8184
Published In/Presented At
Arora, G., Adinugraha, P., Aijaz, A., Vargas Pelaez, A., & Rachko, M. (2022). Pericardial Effusion Secondary to Nilotinib in an Elderly Patient With Chronic Myelogenous Leukemia. Cureus, 14(4), e23855. https://doi.org/10.7759/cureus.23855
Disciplines
Medicine and Health Sciences
PubMedID
35530911
Department(s)
Fellows and Residents
Document Type
Article